Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

Bio-Techne Corporation (TECH) Presents at 53rd Annual Nasdaq Investor Conference Transcript

Seeking Alpha • Dec 9, 2025

Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports complex assay configurations Strengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 compliance MINNEAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and first shipment of its next-generation Leo™ System, powered by Simple Western™ Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples.

PRNewsWire • Dec 9, 2025

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Bio-Techne Corporation (TECH) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

Bio-Techne to Present at Upcoming Investor Conferences

MINNEAPOLIS , Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 8th Annual Evercore Healthcare Conference 2025 December 2, 2025 8:20 AM EST Citi's 2025 Global Healthcare Conference December 3, 2025 3:15 PM EST 53rd Annual Nasdaq Investor Conference December 9, 2025 9:30 AM GMT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

PRNewsWire • Nov 25, 2025

Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript

Bio-Techne Corporation ( TECH ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Tycho Peterson Tycho Peterson Presentation Tycho Peterson Okay. Great. We're going to kick it off.

Seeking Alpha • Nov 20, 2025

Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript

Bio-Techne Corporation ( TECH ) Stephens Annual Investment Conference 2025 November 18, 2025 9:00 AM EST Company Participants James Hippel - Executive VP of Finance & CFO William Geist - President of Protein Sciences Segment Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division [Audio Gap] Is intended to be more of a fireside chat, so I'll stop along the way and poll for any questions. So feel free to chime in as needed.

Seeking Alpha • Nov 18, 2025

Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio

Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine MINNEAPOLIS and SEATTLE , Nov. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.

PRNewsWire • Nov 18, 2025

Bio-Techne Corporation (TECH) Presents at Stifel 2025 Healthcare Conference Transcript

Bio-Techne Corporation ( TECH ) Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. We'll go ahead and get started.

Seeking Alpha • Nov 11, 2025

Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript

Bio-Techne Corporation ( TECH ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Our next session here is the management team from Bio-Techne. We're lucky to be joined by Kim Kelderman, Jim Hippel and Dave Clair.

Seeking Alpha • Nov 10, 2025